134979-01-4, CH2COOH-PEG2-NH2.HCl References: [1] Gribble FM, Reimann F
It is worth noting that in October, AbbVie announced positive results from the head-to-head phase 3 SEQUENCE study, showing non-inferiority compared to Johnson & Johnson's Stelara (predefined non-inferiority margin of 10%)
Within less than 2 years of being on the market, Biktarvy achieved an annual sales revenue of nearly $5 billion, setting a new record for the annual sales of a single HIV drug
Recently, there are plans to submit a marketing application to the FDA for the treatment of chronic obstructive pulmonary disease (COPD), aiming to become the first approved biologic for this serious condition
In a way, personalized healthcare strategies lean toward tailoring therapy based on patient specific traits, genetic signals and disease conditions, which is not something done randomly
Tirzepatide acts on two targets in the body, leading to greater initial weight loss, which also may translate to regaining more weight after switching to orforglipron